Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS
- 23 October 2003
- journal article
- review article
- Published by Elsevier in Clinical Immunology
- Vol. 109 (1) , 89-102
- https://doi.org/10.1016/s1521-6616(03)00207-9
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes?Leukemia, 2003
- Microsatellite instability and hMLH1 promoter hypermethylation in Richter’s transformation of chronic lymphocytic leukemiaLeukemia, 2003
- Alterations of the cyclin D1/pRb/p16INK4A pathway in multiple myelomaLeukemia, 2002
- Inactivation of Tumor Suppressor Genes p15INK4b and p16INK4a in Primary Cutaneous B Cell LymphomaJournal of Investigative Dermatology, 2002
- Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription FactorScience, 2002
- Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinomaProceedings of the National Academy of Sciences, 1998
- Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndromeLeukemia, 1997
- CDKN2 (MTS1/p16INK4A) Gene Alterations in Hematological MalignanciesLeukemia & Lymphoma, 1997
- A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor TypesScience, 1994
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993